18 August 2022

Innovative biomarker assays for cancer research by Biomedica

The identification and validation of biomarkers in cancer is essential to improve our understanding of the disease.


The emergence of novel cancer biomarkers continues to grow as scientists strive to find promising novel therapeutic targets and new prognostic and predictive markers to fight the disease.

Biomedica offers a range of unique biomarker ELISAs for your research.

Advantages of Biomedica ELISA kits

  • Reliable – full validation package
  • Convenient – assay range optimized for clinical samples
  • Easy – ready to use prediluted calibrators & controls
  • Low sample volumes
  • Trusted – widely cited
Biomedica high quality guaranteed

High specificity – known target binding sites through mapping data
The unique specificity of the proprietary antibodies used in the Biomedica ELISA kits ensure that the assays only measure the analyte of interest.

Discover Biomedica´s Biomarker ELISA kits for cancer research

Human total soluble Neuropilin-1 ELISA (BI-20409)
Human Periostin ELISA (BI-20433)
Human soluble Semaphorin 4D ELISA (BI-20405)
Human Osteoprotegerin ELISA (BI-20403)
Human FREE soluble RANKL ELISA (BI-20462)
Human LRG ELISA (BI-LRG)
Human IL-6 ELISA (BI-IL6)
Human VEGF ELISA (BI-VEGF)
Human Angiopoietin-2 ELISA (BI-ANG2)
Other kits can be found here

Learn more

The transmembrane protein Neuropilin-1 (NRP1) regulates tumor biology and has been identified as a checkpoint target (ref. 1). High tissue NRP-1 levels are associated with a poor prognosis in breast cancer patients. In a recent study (ref. 2), German researchers have shown that circulating soluble NRP1 serum levels are an independent marker for poor prognosis in early breast cancer. Soluble Neuropilin-1 was quantified in serum with the highly specific NRP1 ELISA from Biomedica.

The secreted extracellular matrix protein Periostin has evolved as a novel therapeutic target and is a robust marker of glioma malignancy and potential tumor recurrence. It has also been implicated in the pathogenesis of breast cancer as high serum levels of periostin are associated with a poor survival in breast cancer patients (ref. 3). Periostin was quantified in serum with the well characterized Biomedica Periostin ELISA that has been published (ref. 4).

Semaphorin 4D (Sema4D) is a glycoprotein that is emerging as clinical biomarker and as therapeutic target in cancer. It has been associated with cancer progression and the occurrence of bone metastases (ref. 5, 6).

Leucine-rich alpha-2-glycoprotein 1 (LRG1) is a protein that is an important factor involved in pathogenic angiogenesis in cancer. It is abundantly present in the microenvironment of many tumors contributing to vascular dysfunction and thus serving as a potential therapeutic target (ref. 7).

The RANKL/RANK/OPG system contributes to the development of bone metastases and influences tumor biology in earlier stages of cancer (ref. 9). Dysregulation has been widely documented in the context of metastatic bone disease (ref. 10). The Biomedica OPG and RANKL ELISA kits have been widely used in the respective studies.

References

  1. Chuckran CA, Liu C, Bruno TC, Workman CJ, Vignali DA. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. J Immunother Cancer. 2020;8(2):e000967.
  2. Rachner TD, Kasimir-Bauer S, Goebel A, et al. Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer. J Cancer Res Clin Oncol. 2021;147(8):2233-2238.
  3. Rachner TD, Göbel A, Hoffmann O, et al. High serum levels of periostin are associated with a poor survival in breast cancer. Breast Cancer Res Treat. 2020;180(2):515-524.
  4. Gadermaier E, Tesarz M, Suciu AAM, Wallwitz J, Berg G, Himmler G. Characterization of a sandwich ELISA for the quantification of all human periostin isoforms. J Clin Lab Anal. 2018;32(2).
  5. Göbel A, Kuhlmann JD, Link T, et al. Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients. J Bone Oncol. 2019;16:100237.
  6. Mastrantonio R, You H, Tamagnone L. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer. Theranostics. 2021;11(7):3262-3277.
  7. Javaid F, Pilotti C, Camilli C, et al. Leucine-rich alpha-2-glycoprotein 1 (Lrg1) as a novel ADC target. RSC Chem Biol. 2021;2(4):1206-1220.
  8. Infante M, Fabi A, Cognetti F, Gorini S, Caprio M, Fabbri A. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019;38(1):12.
  9. Todenhöfer T, Hennenlotter J, Leidenberger P, et al. Serum receptor activator of nuclear factor κB ligand (Rankl) levels predict biochemical recurrence in patients undergoing radical prostatectomy. BJU Int. 2014;113(1):152-159.
  10. Rachner TD, Kasimir-Bauer S, Göbel A, et al. Prognostic value of rankl/opg serum levels and disseminated tumor cells in nonmetastatic breast cancer. Clin Cancer Res. 2019;25(4):1369-1378.

Innovative biomarker assays for cancer research by Biomedica

Related articles

Newsletter for researchers

We gladly support you by keeping you updated on our latest products and the developments around our services.

Need help? Contact our technical support
Contact